Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics


Catalyst Pharmaceuticals, Inc. (CPRX)

Today's Latest Price: $3.19 USD

0.01 (0.31%)

Updated Oct 23 4:00pm

Add CPRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CPRX Stock Summary

  • The ratio of debt to operating expenses for Catalyst Pharmaceuticals Inc is higher than it is for about merely 0.36% of US stocks.
  • With a year-over-year growth in debt of -100%, Catalyst Pharmaceuticals Inc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for Catalyst Pharmaceuticals Inc comes in at 186.6%, a number that bests 96.54% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Catalyst Pharmaceuticals Inc, a group of peers worth examining would be ATEN, LMNX, VIAV, IVAC, and AXTI.
  • CPRX's SEC filings can be seen here. And to visit Catalyst Pharmaceuticals Inc's official web site, go to www.catalystpharma.com.

CPRX Stock Price Chart Interactive Chart >

Price chart for CPRX

CPRX Price/Volume Stats

Current price $3.19 52-week high $5.83
Prev. close $3.18 52-week low $2.55
Day low $3.11 Volume 947,400
Day high $3.22 Avg. volume 1,950,643
50-day MA $3.26 Dividend yield N/A
200-day MA $4.09 Market Cap 330.05M

Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio


Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.


CPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPRX Latest Social Stream


Loading social stream, please wait...

View Full CPRX Social Stream

Latest CPRX News From Around the Web

Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

Catalyst to appeal ruling in favor of FDA decision on Firdapse's competitor drug

Catalyst Pharmaceuticals slides ([[CPRX]] -7.8%) after a federal judge upheld a previous rule from a Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus and dismissed the company’s lawsuit against the FDA regarding the approval of a rival drug, Ruzurgi for the treatment of Lambert-Eaton Myasthenic Syndrome ((LEMS)) from Jacobus...

Seeking Alpha | September 30, 2020

ROCE Insights For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 …

Benzinga | August 14, 2020

Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

- Firdapse® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse® for Treating LEMS Patients -…

GlobeNewswire | August 10, 2020

Earnings Preview: Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters …

Benzinga | August 7, 2020

Here's How Much Investing $1,000 In Catalyst Pharmaceuticals In 2010 Would Be Worth Today

Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Catalyst’s Solid Decade: One stock that kept pace over the last decade was biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in the past decade came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan … Full story available on Benzinga.com

Benzinga | August 4, 2020

Read More 'CPRX' Stories Here

CPRX Price Returns

1-mo 3.74%
3-mo -32.42%
6-mo -34.90%
1-year -43.04%
3-year 11.15%
5-year -4.49%
YTD -14.93%
2019 95.31%
2018 -50.90%
2017 272.38%
2016 -57.14%
2015 -17.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7366 seconds.